Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
Do you routinely perform molecular profiling for potentially actionable targets in patients with advanced pancreatic cancer?
In your practice, has tumor molecular profiling in pancreatic cancer led to the identification of any actionable targets for which a patient was put on targeted therapy and benefited?
Answer from: Medical Oncologist at Community Practice
In our practice, we reserve the use of molecular broad NGS testing to our patients with metastatic disease, usually at time of first progression. Unfortunately not too many patients will have an actionable mutation, as the most common ones would be in KRAS and TP53. CDKN2A is the most frequently ina...
Sign in or Register to read more